The fucosyltransferase FucT-VII regulates E-selectin ligand synthesis in human T cells by unknown
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Abstract. Selectin-ligands on T cells contribute to the 
recruitment of circulating cells into chronic inflamma- 
tory lesions in the skin and elsewhere. This report pro- 
vides the first evidence that a single fucosyltransferase, 
termed FucT-VII, controls the synthesis of E-selectin 
ligands in human T-lymphoblasts. The FucT-IV trans- 
ferase (the ELFT enzyme), in contrast, constructs 
lower avidity E-selectin ligands and requires enzyme 
levels found only in myeloid cells. Treatment of Jurkat 
cells with phorbol myristate acetate increased the ex- 
pression of sialylated LewisX-related (sLeX-related) 
epitopes and induced the synthesis of E-selectin ligands 
functional at physiologic levels of linear shear-stress. 
Northern analysis revealed a parallel increase in the 
steady-state level of FucT-VII mRNA, but there were 
no increases in the two other leukocyte-associated 
fucosyltransferases (FucT-IV and VI). The stable trans- 
fection of the FucT-VII gene into Jurkat cells induced 
high levels of the sLeX-related epitopes and the synthe- 
sis of E-selectin ligands which equaled or exceeded the 
avidity of those on circulating lymphocytes. The growth 
of T-lymphoblasts under conditions which induced ex- 
pression of the sLe x,a epitopes increased the level of 
FucT-VII mRNA, the synthesis of sialylated-Lewis x 
structures by cell-free extracts and the synthesis of 
E-selectin ligands equal in avidity to those on FucT-VII 
transfectants. In contrast, neither the mRNA levels nor 
activities of the FucT-IV and VI enzymes increased in 
association with E-selectin ligand synthesis in T-lym- 
phoblasts. Myeloid cell lines, unlike lymphoblasts, ex- 
pressed high levels of both the FucT-VII and IV en- 
zymes in conjunction with E-selectin ligands raising the 
possibility that both enzymes contributed to ligand syn- 
thesis. FucT-IV transfected Jurkat cells synthesized low 
avidity ligands for E-selectin but only in association 
with the CDw65 (VIM-2) carbohydrate epitope. Only 
blood neutrophils and myeloid cell lines expressed this 
epitope at the levels associated with E-ligand synthesis 
in the transfectants. In contrast, native Jurkat cells, 
blood monocytes, blood lymphocytes, and cultured 
T-lymphoblasts expressed low levels or none. We con- 
clude that FucT-VII is a principal regulator of E-selec- 
tin ligand synthesis in human T-lymphoblasts while 
both FucT-VII and FucT-IV may direct ligand synthe- 
sis in some myeloid cells. 
F 
UNCTIONAL ligands for the endothelial selectins are 
expressed on 5-20% of circulating a/J3 memory T 
cells (20, 33), a large percentage of 7/8 T cells (13, 
32), natural killer cells (25), and activated B cells (36). 
Correlative studies in several species suggest that these 
molecules participate in recruitment. T-lymphocytes ex- 
pressing carbohydrate epitopes associated with ligands for 
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E-selectin are preferentially recruited into inflammatory 
and malignant diseases involving human skin (7, 39). In 
addition, E-selectin is expressed on the microvascu- 
lature in chronic rheumatoid synovitis (10) and lympho- 
cytes isolated from the synovial pannus bind to E-selectin 
more efficiently than circulating lymphocytes from the same 
patient (35). Temporal associations between E-selectin 
expression and lymphocyte recruitment have been docu- 
mented in human skin (11, 16), ruminant skin (44), and in 
the peribronchial tissue of human xenografts in SCID 
mice (34). Finally, carbohydrate-ligands for E-selectin 
have also been identified on the activated B-lymphocytes 
infiltrating the thyroid in Hashimoto's thyroiditis (36). 
Thus, lymphocytes synthesize glycoconjugate ligands for 
E-selectin and may use them during recruitment into in- 
flammatory lesion. 
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of E-selectin ligands on a/p T cells occurs during the naive 
to memory transition after antigen-induced proliferation 
(33). The prevalence of carbohydrate epitopes associated 
with setectin ligands (e.g., CSLEX1 and HECA452, also 
known as the cutaneous lymphocyte antigen or CLA)  1 de- 
pend on the lymphoid organ in which proliferation occurs 
implying that the microenvironment of the tissue regulates 
ligand synthesis. In vitro experiments support this hypoth- 
esis by showing that the mix of growth factors in the me- 
dium influences the expression of the HECA452 epitope 
(33). Thus, ct/~3 T cells regulate selectin-mediated recruit- 
ment, in part,  through control of ligand synthesis at the 
cell surface. 
The synthetic pathway and control points for construc- 
tion of selectin ligands on T cells are completely unknown. 
Structure/function studies of endogenous selectin ligands 
imply that multiple control points may exist. All selectin 
ligands consist of a protein or lipid "core" coupled to mul- 
tiple  O-  or N-linked oligosaccharide chains (23,  37, 42). 
The oligosaccharide portion of the molecules is essential 
for  function.  For  example,  all  ligands  contain  terminal 
sialic acid and the removal of this sugar alone will inacti- 
vate the molecule (15,  26,  29,  38).  Similarly, all ligands 
contain fucose, and addition of this sugar alone to the ap- 
propriate  sialylated precursor  will  generate a  functional 
molecule (19). However, recent studies with the ligand for 
P-selectin known as PSGL-1 show that expression of the 
appropriate glycosyltransferases is not sufficient for syn- 
thesis of high affinity molecules (40).  As a consequence, 
the expression of functional E-selectin ligands on T  cells 
could be  regulated  through synthesis of the  core  struc- 
tures, the oligosaccharides, or both. 
Finally, the glycosyltransferases  which synthesize the oli- 
gosaccharide portion of the selectin ligands on leukocytes 
have not been  identified. The finding that fucosyltrans- 
ferases capable of synthesizing sialylated Lewis  x (sLC) re- 
sult in expression of functional ligands for E-selectin  in 
COS and CHO cells suggests that one or more of these en- 
zymes participates in the synthesis of ligands on leukocytes 
(18, 19). Cloning of the ELFT fucosyltransferase (now des- 
ignated fucosyltransferase-IV or FucT-IV) from the HL-60 
cell line led to the hypothesis that this enzyme regulates 
the synthesis of ligands in leukocytes (9, 24). However, the 
low efficiency of sLe  x synthesis and E-selectin binding ac- 
tivity in some FucT-IV transfected CHO strains (17), and 
the  subsequent  identification of two  additional fucosyl- 
transferases in leukocytes (41)  raises the possibility that 
other enzymes are involved. 
This study examines the role of fucosyltransferases in 
the synthesis of E-selectin ligands on normal and malig- 
nant T-lymphoblasts. The investigation reveals that con- 
trol of terminal glycosylation regulates adhesive activity 
and  that  the  fucosyltransferase FucT-VII,  rather  than 
FucT-IV, is the key enzyme. 
1. Abbreviations used in this paper: CHO-E, CHO cells expressing E-selec- 
tin; CLA, cutaneous lymphocyte antigen; HUVE, human umbilical vein 
endothelium; FucT-III-VII,  fucosyltransferases III-VII;  sLe  x,  sialylated 
LewisX; MDPBL, monocyte depleted peripheral blood lymphocyte; MFI, 
mean fluorescence intensity; PMA, phorbol myristate acetate; TNF, tu- 
mor-necrosis factor. 
Materials and Methods 
Cell Culture 
Jurkat cells were grown in RPMI-1640 (GIBCO-BRL, Grand Island, NY) 
supplemented with 10%  FCS. Ceils were stimulated with 10 nM PMA 
(Sigma Chem. Co., St. Louis, MO) for 6--8 d  before analysis of fucosyl- 
transferase activity and selectin-ligand expression. The fucosyltransferase 
transfected  T-lymphoblastic cell  lines were  grown  in  RPMI-1640  with 
10%  FCS and G418 (GIBCO-BRL) to maintain the transfected pheno- 
type. Human lymphocytes isolated from vaccine-primed lymph node cells 
(5) were activated by cross-linking of CD3 and expanded in interleukin-2 
(10 U/ml, recombinant-human, a gift from Genentech, South San Fran- 
cisco, CA) supplemented media as described in the Results section. 
Flow Cytometry 
Indirect immunofluorescence  staining and flow cytometry were conducted 
as previously described using light-scatter gating to identify the popula- 
tions of interest (14). The anti-VIM-2 (Immunotech, Westbrook, ME), 
CSLEX1  (Amer. Type Culture Collection, Rockville, MD), HECA-452 
(Dr. Louis Picker, University of Texas Southwestern School of Medicine, 
Dallas, TX), anti-Lewis  X (MMA, Becton Dickinson, San Jose, CA), and 
isotype-matched control antibodies were used at concentrations ranging 
from 10-20 l~g/ml. The FITC- and phycoerythrin (PE)-conjugated second- 
ary reagents (Immunotech) were used at saturating concentrations, gener- 
ally at a 1:50-1:100 dilution of the commercial stock solution. 
The FACScan photomultiplier was set to a mean fluorescence intensity 
(MFI) of 6-10 for the isotype-matched control population (on a four-decade 
log scale) before reading the test ceils. The fluorescence intensity mea- 
surements and the histograms were made with the Winlist Listmode anal- 
ysis program (Verity Software, Topsham, MA). The histograms in the fig- 
ures are  plotted  on four-decade logarithmic scales with  maximal peak 
heights normalized to the negative control population so that differences 
in the prevalence of positive cells can be compared. In Table I, the "posi- 
tive ceils" were defined as the fraction which exceeded the fluorescence 
intensity of 98% of the cells in the isotype-matched control. The MFI was 
the numerical mean of the fluorescence histograms for the positive popu- 
lation. 
RNA Preparation and Analysis 
Total RNA preparation, Northern blotting, and analysis were performed 
as described (2). Briefly, cells grown in suspension culture were harvested 
by centrifugation. The cells were triturated in the Trizol reagent (GIBCO- 
BRL) which both lysed cells and extracted the RNA. Total RNA was sol- 
ubilized in chloroform and precipitated with isopropanol. The RNA pellet 
was washed with 75% ethanol, dried under a vacuum, dissolved in DEPC- 
treated water, and stored at -70°C until used. 
Twice-purified mRNA was used in the Northern analyses due to the 
low abundance of transcripts for the glycosyltransferases. Poly (A) mRNA 
was separated from total RNA over an oligo-(dT)-cellulose column (Boeh- 
ringer Mannheim Biochemicais, Indianapolis, IN). The bound mRNA was 
eluted with 0.1  M  KOH, reapplied  to the oligo-(dT)-cellulose column, 
eluted, and precipitated in ethanol/potassium containing 20 ~g of glyco- 
gen (Boehringer Mannheim Biochemicals). The RNA precipitates were 
dried on a rotary evaporator, resuspended in DEPC-treated water, elec- 
trophoresed (7-10 i~g/lane) on a denaturing 1% agarose-formaldehyde gel 
and analyzed by Northern blotting. 
Northern Blot Analysis 
Northern blotting was performed following capillary transfer of mRNA 
from the  agarose-formaldehyde gels  to  nylon membranes (Hybond-N, 
Amersham Corp., Arlington Heights, IL). The mRNA was cross-linked to 
the membrane (UV light, 5 min), rinsed in 6X SCC buffer, and baked for 
2 h at 80°C. The blot was prehybridized for 6-20 h at 42°C in buffer con- 
sisting of 5 x  SCC, 5 x  Denhardt's solution, salmon sperm DNA, 50% for- 
mamide and 50 mM sodium phosphate, pH 6.5.  The fucosyltransferase 
and p-actin probes were labeled with [32p] using a Random Primed label- 
ing kit  (Boehringer Mannheim Biochemicals) and a-[32P]dCTP  (Amer- 
sham Corp.) following the manufacturer's protocol. The blot was hybrid- 
ized with the 32p-labeled probe at a concentration of at least 10 x  106 cpm/ 
ml in the prehybridization buffer for 24 h at 42°C, followed by four washes 
for 5 rain each in 2x SCC containing 0.2% SDS. The blot was then washed 
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(65°C, 30 min), wrapped in Saran and analyzed using a PhosphorImager 
(Molecular Dynamics, Sunnyvale, CA). Blots were stripped with a solu- 
tion of boiling 0.2% SDS in water and examined for bound radioactivity 
before being probed for expression of a distinct mRNA. The blots were 
probed  sequentially with cDNAs specific for FucT-VII, FucT-IV, a  se- 
quence common to FucT-III, V, and VI, and finally 13-actin. 
The Phosphorlmager produced a digitized image reflecting the distri- 
bution of counts on the blot. The region of the blot containing each mRNA 
species was identified by a  positive control  run in a  parallel  lane. The 
HL60 and U937 cells served as positive controls for FucT-VII and FucT-IV 
mRNA (41).  Colo205  cells served as positive  control  for  the common 
FucT-III,V,VI probe (41). The appropriate regions were cropped and as- 
sembled into the composite figures using Photostyler (Aldus, Inc., Seattle, 
WA) and Stanford Graphics (Visual Numerics, Houston, TX). 
Enzyme Assay for Fucosyltransferase- VII 
and Fucosyltransferase-IV 
Fucosyltransferase assays were carried out as described (27). Briefly, cells 
grown in suspension culture were collected by centrifugation, washed twice 
in Dulbecco's PBS, and resuspended in 1% Triton X-100 at 50-100 ×  106 
cells/mL The reaction cocktails contained the following constituents in a 
total volume of 20 p.L: extract from 1-5 X 10  s cells, 3 p.M GDP-[3H]Fu  - 
cose or [14C]Fucose  (American Radiolabeled Chemicals, Inc., St. Louis, 
MO); 5 mM of the carbohydrate acceptor, 5 mM ATP, 10 mM L-fucose; 10 
mM MnCI2; 0.5% Triton X-100 and 25 mM cacodylate buffer, pH 6.2. The 
carbohydrate  acceptor  for  the FucT-IV  assay was  N-acetyllactosamine 
(LacNAc, provided by I.J. Goldstein, University of Michigan, Ann Arbor, 
MI) and the acceptor for the FucT-VII assay was sialyl a2,3-LacNAc (Ox- 
ford Glycosystems, Rosedale, NY). Incubations were carried out at 37°C 
for 2 h (FucT-IV) or 3 h (FucT-VII). The reactions were stopped by the ad- 
dition of 20 Ixl of ethanol and 560 p.l of water (FucT-IV) or 580 p.l of 5 mM 
POa,  pH  6.8  (FucT-VII).  The  reaction  products  were  isolated  over 
Dowexlx4-400, formate  form  (FucT-IV)  or  Dowexlx8-400,  phosphate 
form (FucT-VII), and analyzed by scintillation counting. Results are re- 
ported as picomoles product formed per hour per 106 cells. 
Parallel-Plate Flow Assays 
The parallel-plate  flow chamber used in these studies and the general 
technique has been described (1). Monolayers of either human umbilical 
vein endothelium (HUVE, passage 3-5) or transfected CHO cells expressing 
E-selectin (CHO-E) were grown on 35-mm Petri-plates. The HUVE cells 
were  treated  with  recombinant  human tumor-necrosis factor  (TNF-10 
nanograms/ml, PeproTech, Inc., Rocky Hill, NJ) for 4-6 h before conduct- 
ing experiments. Experiments on TNF-treated  HUVE  were  conducted 
with the ~t4- and 132-integrins blocked by the monoclonal antibodies HP2/1 
(Immunotech) and TS1/18 (ATCC), respectively. The remaining adhesive 
interactions are E-selectin dependent since addition of the E-selectin spe- 
cific monoclonal antibody 7A9 (ATCC)  to  the antibody cocktail  com- 
pletely eliminated all interactions. Adhesive interactions on CHO-E were 
completely inhibited by treatment with streptococcal neuraminidase (Gen- 
zyme, Inc., Cambridge, MA) or blockade with the monoclonal antibody 7A9. 
Data analysis was conducted with software developed in conjunction 
with Compix, Inc. (Mars, PA) for use on their C-Imaging 1280 Computer- 
ized Morphometry System (Compix, Inc.). This module (termed Celltrak) 
uses computerized morphometry to track the leukocytes in real time as 
they cross over the monolayer expressing the adhesion receptor of inter- 
est. Sequential images of the tracked cells were digitized and matched on 
the basis of their trajectories and morphometric characteristics. The dis- 
tances between the centers of the paired cells were measured and the ve- 
locities calculated using the time-delay between the captured images. A 
time-delay of 3-4 s was used since this provided optimal resolution for cells 
rolling at velocities <50  ixm/s. The Celltrak program acquired the digi- 
tized images, measured velocities of all the identified cells, compiled sta- 
tistics from the prescribed number of fields and generated histograms of 
the velocity distribution. A measurement derived from a single pair of images 
is referred to as an "event." A given cell may contribute to one or more 
events since cells which remain in contact with the monolayer are sampled 
multiple times. Therefore, the number of events is a measure of the preva- 
lence of adhesive interactions but not the absolute number of adherent cells. 
Each histogram consists of 1,000-4,000  events collected from 60-100 sequen- 
tim fields covering a 2~-min period of observation. The velocity histograms 
were plotted using Stanford Graphics (Visual Numerics, Houston, TX). 
Transfection of T-Lymphoblastic Cell Lines 
The construction of the FucT-IV or FucT-VII expression vectors has been 
described (27, 45). Transfection of Jurkat ceils with linearized vectors con- 
taining FucT-IV or FucT-VII was carried out using a Cell-Porator  ~ Elec- 
troporator  system (GIBCO-BRL)  as follows: 800  Ixl  of 107 cells/ml in 
HEBS buffer (20 mM Hepes, pH 7.05, 137 mM NaCI, 5 mM KCI, 0.7 mM 
PO4, 6 mM dextrose) were pulsed at 280 V, 880 t.~Farads in a sterile elec- 
troporation cell. Allquots of the electroporated cells were added to nor- 
mal medium in T25 flasks and grown for 3 d. After 3 d, 2 mg/ml of G418 
was  added  to  select  for  stable  transfectants. Resistant cells  appeared 
within 2~1 wk at which time the bulk cultures were examined for expres- 
sion of carbohydrate epitopes and functional selectin ligands. Limited- 
dilution cloning was conducted to stabilize and enhance the prevalence of 
transfectants with the desired phenotype. The selected bulk cultures and 
clones were maintained in media with 0.4 mg/mL of G418. 
Results 
Previous studies indicated that selectin ligands on T  cells 
are synthesized in response to mitogenic stimuli. Since pro- 
tein kinase C regulates many transcriptional responses in 
T cells during mitogensis (22), we examined the effects of 
the agonist phorbol myristate acetate (PMA) on the Jurkat 
cell line.  This line retains many of the T cell responses to 
mitogens including transcriptional induction of IL-2, IL-2 
receptors,  and  L-selectin  (14).  Addition of PMA  to  the 
growth medium increased the prevalence and density of 
two epitopes  defined by terminal  sialylated,  fucosylated 
N-acetyllactosamine  structures,  HECA452  and  CSLEX1. 
The HECA452 antibody reacts with glycoconjugates carry- 
ing sialylated Lewis  x (sLeX), sialylated Lewis  a and other yet 
to be defined capping structures (3). The CSLEX1 antibody 
reacts  with  glycoconjugates carrying  the  sLe  x tetrasac- 
charide primarily (6). These two epitopes will subsequently 
be referred to as sLeX-related.  The response varied mark- 
edly in different clonal isolates of Jurkat. Fig. 1 shows the 
time course for upregulation in the JS9-78 clone used for 
the experiments depicted in Figs. 2 and 3. Expression of 
the HECA452 epitope increased within 24--48 h and then 
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Figure 1. Time course for induction of HECA452 •  and CSLEX1 
[] epitopes on phorbol myristate acetate  (PMA)-treated Jurkat 
cells. 5-10 nM PMA was added  to the  culture medium for the 
times indicated followed by single color flow cytometry to mea- 
sure expression of the  two epitopes.  Each time point  includes 
data from 3-13 independent  experiments. The error bars define 
the standard  error  for each data set. The number  in bold print 
above each column is the average of the mean fluorescence inten- 
sities (MFIs) for the pooled data. 
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epitope  lagged  behind  HECA452;  however,  the  preva- 
lence and densities of both were significantly elevated af- 
ter 6-8 d  of culture in 5-10 nM PMA. Jurkat cells which 
survived and proliferated in the presence of 5  nM PMA 
for 30--60 d showed the highest densities of both carbohy- 
drate epitopes. 
Fig. 2 shows that 6--8 d of treatment with PMA upregu- 
lated expression of the sl_~X-related epitopes (A) and E-selec- 
tin mediated rolling activity in Jurkat cells (B). These ex- 
periments used human umbilical vein endothelium treated 
with tumor-necrosis factor for 4-6 h  (TNF-HUVE). The 
velocity measurements were made with the a4- and 132-inte- 
grins on the Jurkat cell blocked. The adhesive interactions 
observed under these conditions are completely inhibited 
by the E-selectin specific monoclonal antibody 7A9. The 
untreated  Jurkat  cells  showed  virtually  no  interactions 
with  TNF-HUVE.  PMA  treatment  increased  the  preva- 
lence of E-selectin-dependent adhesion. The low number 
of  adhesion  events  indicated  that  only  a  subset  of  the 
PMA-treated cells expressed high avidity ligands. This be- 
havior is consistent with the observation that high level ex- 
pression of sLeX-related epitopes was confined to a subset 
of the treated cells (A). 
PMA  treatment  selectively  increased  the  steady-state 
level of the FucT-VII mRNA in Jurkat ceils. The increase 
was  readily  detected  by Northern  analysis  at  the  6-8  d 
time point  (Fig. 3)  and  in Jurkat cells treated for >60  d 
with PMA (not shown). In contrast, FucT-IV (ELFT) tran- 
scripts were  barely detectable  by Northern  blot analysis 
despite using relatively large amounts of purified mRNA 
(7 Ixg poly-A purified mRNA per lane) and prolonged ex- 
Figure 3.  Induction of FucT-VII mRNA in PMA-treated Jurkat 
cells. The figure shows the steady-state prevalence of  mRNA species 
in untreated (Jurkat) and PMA-treated (Jurkat+PMA) cells. North- 
ern analysis of 7-10 Ixg of purified messenger RNA provided mea- 
sures of the fucosyltransferase  and 13-actin gene products. 
posures of the 32P-labeled blot in the Phosphorlmager (14 d). 
The  FucT-IV  probe  readily  detected  FucT-IV  specific 
transcripts  in  an  equal  amount  of purified  mRNA  from 
myeloid cell lines (see Fig. 7).  In addition, no increase in 
the mRNA levels of FucT-III, FucT-V, or FucT-VI were 
detected using a  probe reactive with homologous regions 
of  these  three  gene  products.  This  probe  reacted  with 
mRNA from the Colo205 cell line (data not shown) which 
expresses high levels of the FucT-III enzyme (41). 
The capacity of the FucT-VII gene product alone to reg- 
ulate E-selectin ligand synthesis in T cells was explored by 
constructing  stable  FucT-VII transfectants  in  the  Jurkat 
cell line (FucT-VII-Jurkat). The subcloned transfectants ex- 
pressed the sLeX-related epitopes at the highest levels ob- 
served on peripheral blood lyrnphocytes (Fig. 4 A).  The 
Figure 2.  Comparison of carbohydrate 
epitopes  and  E-selectin  ligands  on 
PMA-treated Jurkat cells. Jurkat cells 
were stimulated  with  10 nM PMA for 
6--8 d. The figure shows the expression 
of carbohydrate epitopes (A) and func- 
tional ligands for E-selectin  (B) on un- 
treated  (Jurkat)  and  PMA-treated 
(Jurkat+PMA)  cells. The  histograms 
in A show the prevalence of the epitopes 
CSLEX1 and HECA452 in a sample of 
104 cells after indirect  immunofluores- 
cence  staining  with  a  phycoerythrin- 
tagged secondary reagent. The modes 
for each histogram are set to the same 
height so that the induction  of the car- 
bohydrate epitopes is clearly seen. The 
histograms in B show the velocity dis- 
tribution  of the  cells  adhering  to  tu- 
mor-necrosis factor treated human um- 
bilical vein  endothelium at 1.9  dynes/ 
cm  2 with both the a4- and 132-integrins 
blocked (see text). The "# events" (up- 
per right corner of histograms)  are pro- 
portional to the overall prevalence of 
adhesive interactions  during the period 
of  observation  (see  Materials  and 
Methods).  The mean leukocyte rolling 
velocity (above arrow, standard devia- 
tion in parenthesis) reflects the avidity 
of the adhesive interactions. 
The Journal of Cell Biology,  Volume 133, 1996  914 FucT-VII-Jurkat cell line also expressed high avidity E-selec- 
tin  ligands  capable  of  mediating  slow  rolling  on  TNF- 
HUVE at physiologic levels of linear shear-stress (Fig. 4 
B). In addition, the FucT-VII-Jurkat showed a higher prev- 
alence of adhesive interactions (i.e.,  eightfold more events) 
and a slower mean rolling velocity than monocyte-depleted 
peripheral  blood  lymphocytes (MDPBL).  This behavior 
mirrored the overall prevalence, and, to some extent, the 
level  of  sLeX-related  epitopes  in  the  two  populations. 
Transfection of the vector alone did not result in the ex- 
pression of either the sLeX-related epitopes or functional 
E-selectin ligands (not shown). 
The next series of experiments capitalized on the discov- 
ery that minor changes in the growth media dramatically 
altered the expression of selectin ligands on cultured nor- 
mal  T-lymphoblasts.  The  growth  protocols consisted  of 
two activation/expansion cycles as described for produc- 
tion of vaccine-primed lymph node cells before infusion 
for the adoptive immunotherapy of renal cell carcinoma 
(5, 43). Each cycle began with cross-linking of the T  cell 
receptor on plate-immobilized CD3 (48 h) followed by ex- 
pansion in IL-2 supplemented media for 6 d in gas-perme- 
able bags. This protocol resulted in a 50-100-fold increase 
in the absolute number of CD8 cells with >90% viability 
after 15 d. At 15 d, the populations consisted of 80-90% 
CD8 cells and 10-20% CD4 cells. 
Fig.  5  shows  the carbohydrate epitopes and E-selectin 
binding activity for lymph node lymphocytes expanded in 
the serum-free medium XVIVO15 (Bio-Whittaker, Walk- 
ersville, MD), XVIVO15 supplemented with 10% human 
AB serum (HAB-Sigma Chemical Co.) or RPMI with 10% 
HAB.  Growth  in  XVIVO15  produced  CD8-blasts  uni- 
formly positive for CSLEX1 and HECA452 epitopes (Fig. 
5 A). These cells rolled and arrested on E-selectin trans- 
fected CHO cells at 1.9 dynes/cm  2 of shear-stress confirm- 
ing the presence of functional ligands (Fig. 5 B). Northern 
analysis of twice purified poly-A messenger RNA showed 
massive induction of mRNA specific for the fucosyltrans- 
ferase FucT-VII but no evidence for induction of mRNAs 
for FucT-III-VI (Fig. 6 A). In contrast, growth in HAB- 
supplemented mediums resulted in cell populations with a 
low prevalence of CSLEX1 and HECA452 epitopes, low 
E-selectin binding activity and much lower levels of FucT- 
VII mRNA by Northern analysis (Figs. 5 and 6). Finally, 
the level of sLeX-related epitopes and functional E-selectin 
ligands correlated with the level of sLe  x synthesis by cell- 
free extracts (Fig. 6 B). The Le  x synthetic activity, in contrast, 
was the same regardless of the prevalence of sLeX-related 
epitopes and E-selectin ligands in the blast populations. 
As noted above, FucT-IV activity was not significantly 
different  in  lymphoblasts  with  and  without  E-selectin 
ligands. However, recent intravital studies in FucT-IV knock- 
out animals showed an increase in selectin-dependent neu- 
trophil rolling velocities in  cremasteric venules implying 
that the selectin-ligand density/affinity was reduced in en- 
zyme deficient cells (Thall, A., U. von Andrian, and J.B. 
Lowe,  manuscript  in  preparation).  We,  therefore,  con- 
ducted several experiments to determine whether this en- 
zyme directed the synthesis of selectin ligands  in human 
leukocytes. 
Stable FucT-IV transfectants constructed in Jurkat cells 
(FucT-IV-Jurkat) rolled on E-selectin under shear; how- 
ever, the mean velocity was higher than either the FucT- 
VII-Jurkat  cells  or  the  myeloid cell  lines  (Fig.  7).  The 
Figure  4.  Induction  of  carbohydrate 
epitopes  and  E-selectin  ligands  by 
overexpression  of the FucT-VII  gene 
product  in  Jurkat  cells. Jurkat  cells 
were  transfected  with  an  expression 
vector  containing  the  FucT-VII  and 
G418  resistance  genes.  Transfectants 
were selected in G418 containing me- 
dia and subcloned for expression of the 
CSLEX1 epitope. The figure shows the 
expression of carbohydrate epitopes (A) 
and  functional  ligands for  E-selectin 
(B)  on  the  transfectants  (FucT-VII- 
Jurkat) and monocyte-depleted  periph- 
eral blood lymphocytes (MDPBL). See 
Fig. 1 for addition information on the 
assays. 
Knibbs et al. Regulation of  E-Selectin Ligand Synthesis  in Lymphocytes  915 Figure 5.  Coregulation of carbohydrate epitopes and E-selectin ligands during T  cell proliferation in vitro. Vaccine-primed lymph 
node cells (VPLNs) were expanded in serum-free or serum-supplemented media. The figure shows the results of flow cytometry (A) 
and parallel-plate adhesion assays (B) on VPLNs grown in the serum-free medium XVIVO15 (XVIVO), XVIVO15 with 10% human 
AB serum (XVIVO+HAB) or RPMI with 10% human AB serum (RPMI+HAB). The assays were conducted as described in Fig. 1 ex- 
cept that Chinese hamster ovary cells transfected with the full-length E-selectin gene (CHO-E) were substituted for TNF-HUVE. 
FucT-IV-Jurkat cells showed a  10-15-fold increase in ex- 
pression of the CDw65 epitope (originally known as VIM-2: 
[21]) but not the structurally distinct CSLEX1 or HECA452 
epitopes (Table I). The  level of CD15,  the Le  x structure, 
increased as well. The myeloid cells lines (HL60 and U937) 
and  blood  neutrophils  were  the  only cells constitutively 
expressing the  CDw65  epitope at  or above the levels on 
the FucT-IV-Jurkats. Monocytes and nontransfected Jurkat 
cells expressed the epitope to a  lesser degree while blood 
lymphocytes  and  T-lymphoblasts  cultured  in  XVIVO15 
were essentially devoid of the structure.  The  constitutive 
expression of CD15 in cell lines and blood leukocytes var- 
ied in  concert with  CDw65;  however,  its level was  consis- 
tently  higher.  In  contrast,  the  CSLEX1  and  HECA452 
epitopes were expressed on all leukocytes with functional 
ligands for E-selectin and did not vary in concert with ei- 
ther CDw65 or CD15. In fact, overexpression of FucT-VII 
in Jurkat  cells eliminated the  CDw65  epitope and  mark- 
edly reduced CD15 expression. 
In the final experiment, the levels of fucosyltransferase 
mRNA  and enzyme activity in the two CSLEX1/CDw65 
positive myeloid cell lines were compared to the CSLEX1 
positive, CDw65 negative lymphoblasts grown in XVIVO15 
(Fig. 8). The Northern blots showed the relative levels of 
Figure 6.  Induction of FucT-VII mRNA and sialyl-Lewis  X  ligands 
during T  cell proliferation in vitro. Vaccine-primed lymph node 
cells (VPLNs)  were  expanded  in  serum-free or serum-supple- 
mented media. The figure shows the steady-state prevalence of 
mRNA species (A) and the fucosyltransferase activities in cell- 
free  extracts  (B)  of VPLNs  grown  in  the  serum-free medium 
XVIVO15  (XVIVO), XVIVO15  with  10%  human  AB  serum 
(XVIVO+HAB)  or  RPMI  with  10%  human  AB  serum 
(RPMI+HAB).  The rate of sialylated Lewis  x and Lewis  x synthe- 
sis on exogenous sialyl-LacNAc  and LacNAc acceptors (in pmol/ 
h/106 cells, standard deviation in parentheses) provided measures 
of fucosyltransferase activities. 
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kat transfectants  and myeloid cell lines 
on  CHO-E.  Jurkat  cells  were  trans- 
fected with expression vectors contain- 
ing  either  the  FucT-VII or  FucT-IV 
genes as described  in Fig. 2. The bulk 
FucT-VII transfectants  expressed the 
CSLEX1  epitope  while  the  FucT-IV 
transfectants  expressed  the  VIM2 
epitope exclusively  (see text).  There- 
fore, the lines were subcloned  for opti- 
mal  expression  of  the  CSLEX1  and 
VIM2  epitopes,  respectively,  before 
functional analysis. The figure compares 
the velocity distributions of the FucT-IV 
transfectants  (FucT-IV-Jurkat),  the 
FucT-VII  transfectants  (FucT-Vll- 
Jurkat),  and  the  myeloid  cell  lines 
U937 (U937) and HL-60 (HL-60). See 
Fig. 1 for additional information on the 
velocity measurements. 
the fucosyltransferase mRNAs in approximately equivalent 
amounts  of  twice-purified  mRNA.  FucT-IV  transcripts 
were detected in both myeloid cell lines at levels approach- 
ing the FucT-VII mRNA. In contrast, only the FucT-VII 
transcripts  were  sufficiently  abundant  in  the  T-lympho- 
blasts to be detected on the blots. The cell-free enzyme as- 
says provided a direct comparison of relative synthetic ac- 
tivities. The sLe  x synthesis was relatively high in all three 
populations while Le  x synthesis was 10-16-fold higher in 
the  myeloid  cell  lines.  Thus,  the  steady-state  levels  of 
FucT-VII mRNA and sLe  x synthetic activity in these cells 
paralleled  the  expression  of  the  sLeX-related  epitopes 
shown in Table I. In contrast, the level of FucT-IV mRNA 
and Le  x synthetic activity paralleled the expression of the 
CD15 and CDw65 epitopes. 
Discussion 
This  report  establishes  a  role  for  the  fucosyltransferase 
FucT-VII in the synthesis and regulation of E-selectin ligands 
on human T-lymphoblasts. First, in PMA-treated Jurkat cells 
and cultured T-lymphoblasts, the steady-state level of FucT- 
VII mRNA correlates with the prevalence of sLeX-related 
epitopes and  the  construction  of physiologically relevant 
E-selectin  ligands.  In contrast,  transcripts  for the  leuko- 
cyte-associated fucosyltransferases FucT-IV and FucT-VI 
are essentially undetectable  by Northern  analysis in  up 
to  7  p~g  of purified  messenger  RNA  regardless  of the 
level of E-selectin  ligands  on  T-lymphoblasts.  Second, 
the pattern of sialylated N-acetyllactosamine epitopes on 
the surface of FucT-VII transfected Jurkat cells (CSLEX1 
and HECA452 positive, CD15 low and CDw65 negative) 
recapitulates the phenotype observed on cultured T-lym- 
phoblasts (Table I) and reported for T-lymphoblasts syn- 
thesizing  E-selectin  ligands  in  vivo (33).  FucT-IV trans- 
fectants,  in  contrast,  express high  levels of CDw65  and 
CD15 and no CSLEX1 or HECA452. Third, the avidity of 
the ligands synthesized by the FucT-VII transfectants and 
the cultured T-lymphoblasts are similar. FucT-IV transfec- 
tants, on the other hand, produce only low avidity ligands. 
Finally, the fucosyltransferase activity associated with the 
synthesis of E-selectin ligands in T-lymphoblasts best fits 
the substrate specificity of the FucT-VII enzyme. The cell- 
free assays found that synthesis of sLe  x on the 2,3  sialyl- 
LacNAc substrate increases in conjunction with E-selectin 
binding activity. The synthesis of Le  x on the LacNAc sub- 
Figure 8.  Comparison of fucosyltransferases  in myeloid cell lines 
and T-lymphoblasts expressing functional  ligands for E-selectin. 
The figure shows the steady-state prevalence of mRNA species (A) 
and the fucosyltransferase activities in cell-free extracts (B) of two 
myeloid cells lines (U937, HL-60) and VPLNs grown in the se- 
rum-free medium XVIVO15 (XVIVO-blasts). See Fig. 2 for addi- 
tional information on the Northern analyses and enzyme assays. 
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and T-Lymphoblasts 
FucT-IV  FucT-VII  T-blasts 
U937  HL60  PMNs  Monos  Lymph  Jurkat  Jurkat  Jurkat  (XVIVO) 
CD15  2148 ±  208  3936 ±  348  6758 +  449  888 --- 34  191  +  13  1133 ±  36  5516 ±  157  370 ±  5  437 ±  20 
(97%)  (100%)  (100%)  (91%)  (13%)  (100%)  (100%)  (92%)  (95%) 
1032 ±  12  2815 ±  109  878 ±  20  189 -  7  194 ±  33  119 ±  6  1095 ±  10  -  - 
CDw65 
(100%)  (100%)  (90%)  (83%)  (2%)  (77%)  (100%)  (<1%)  (<1%) 
614 ±  46  3176 -  185  2017 ±  79  444 ±  13  514 --- 59  -  -  1841  ±  73  1513 ±  86 
C S LEX 1 
(100%)  (99%)  (82%)  (93%)  (16%)  (<1%)  (0%)  (100%)  (76%) 
1258 ±  30  2482 ±  79  1585 ±  39  920 ±  17  2219 ±  71  -  -  921  ±  39  2173 ±  92 
HECA452 
(100%)  (97%)  (82%)  (87%)  (17%)  (<1%)  (0%)  (100%)  (100%) 
Indirect immunofluorescence and flow cytometry were conducted as described in Materials and Methods. The MFI _+ SD (N =  3) and the mean percent of positive cells (in paren- 
theses) is reported. The MFI for subpopulations of < 1% are not statistically significant. The samples were run in a single batch to minimize variations due to culture conditions, re 
agents, and instrument settings. However, the values are representative of 4-20 independent experiments. PMNs (neutrophils), Monos (monocytes), and lymphs (lymphocytes) 
were isolated from heparinized peripheral blood over Neutrophil Isolation Medium (Cardinal Associates, Santa Fe, NM). T-blasts refers to T  cells cultured for 2 wk in the 
XVIVO 15 medium. 
strate, in contrast, is not significantly different in extracts 
of E-selectin ligand positive and negative populations. Of 
the three fucosyltransferases detected by RT-PCR in nor- 
mal human  lymphocytes (FucT-IV, FucT-VI, and FucT- 
VII[41]), only the FucT-VII enzyme shows this substrate 
specificity in cell-free assays and transfectants (8, 17, 27, 
41). We conclude that the FucT-VII enzyme catalyzes the 
final step in the synthesis of E-selectin ligands on T  cells 
and that regulation of its activity during T  cell prolifera- 
tion controls the level of binding activity. 
The CD15 (Le  x) epitope expressed on Jurkat cells and 
cultured T-lymphoblasts cannot be attributed to the FucT- 
VII enzyme. This enzyme shows a marked predilection for 
2,3 sialyl-N-acetyllactosamine over N-acetyllactosamine sub- 
strates in cell-free assays (8, 27). In addition, transfection 
of the FucT-VII gene-product into Jurkat increases sLe  x- 
related epitope expression but decreases the level of the 
Le  x epitope (Table I). Thus, an increase in the intracellular 
concentration of the FucT-VI! appears to divert endogenous 
N-acetyllactosamine substrates away from the pathway re- 
sponsible for Le  x synthesis. This implies that a distinct, en- 
dogenous  fucosyltransferase  functions  in  this  pathway. 
FucT-IV and VI mRNAs were not detected in Northern 
blots of T-lymphoblasts. However, in previous studies, the 
more sensitive RT-PCR analysis identified transcripts  in 
both Jurkat  cells  and  pooled peripheral  blood  lympho- 
cytes (41). These two enzymes show markedly different 
synthetic activities. The FucT-IV enzyme synthesizes Le  x 
more  efficiently than  sLe  x in  both  cell-free assays  and 
CHO-transfectants (8, 17, 41). The same applies to Jurkat 
cells since FucT-IV transfectants increase Le  x (CD15) ex- 
pression more than fivefold but do not synthesize either 
the CSLEX1 or HECA452 epitopes (Table I). The FucT- 
VI gene, in contrast, produces high levels of both the Le  x 
and  sLeX-related  epitopes  on  CHO-transfectants  (45). 
However, Le  x and sLeX-related epitopes are regulated in- 
dependently on Jurkat cells and cultured T-lymphoblasts. 
Consequently, the FucT-IV enzyme most likely controls 
Le  x synthesis in these cells and relatively low steady-state 
levels of mRNA are sufficient for activity. 
Previous studies  concluded that  the  FucT-IV enzyme 
also synthesizes 2,3 sialyl-N-acetyllactosamine epitopes in 
CHO-transfectants. However, they are divided on the na- 
ture of the structures made and whether the enzyme actu- 
ally synthesizes functional ligands for E-selectin in intact 
cells.  Specifically,  some  strains  of FucT-IV  transfected 
CHO cells produce sLe  x epitopes (9) while others synthe- 
size the VIM-2 (CDw65) epitope exclusively (17, 21). In 
these  studies,  only FucT-IV transfected CHO  cells with 
sLe  x epitopes on their surface show E-selectin binding ac- 
tivity. These observations lead to the hypothesis that the 
FucT-IV enzyme regulates  E-selectin binding on  leuko- 
cytes through synthesis of the sLe  x structure (9). 
The  current  study  shows  that  in  human  leukocytes, 
FucT-IV constructs E-selectin ligands in association with 
high levels of the CDw65  epitope exclusively. The sLe  x- 
related epitopes CSLEX1 and HECA452 are not expressed 
by FucT-IV transfected Jurkat  cells; thus  the  E-selectin 
"ligands" synthesized by this enzyme may differ structur- 
ally from those specified by the FucT-VII enzyme. Fur- 
thermore, the ligands appear to be low in density and/or 
avidity since the FucT-IV transfectants show fewer inter- 
actions and roll faster than the FucT-VII transfectants or 
myeloid ceils (Fig. 7). Whether the CDw65 epitope forms 
part of an E-selectin ligand on leukocytes cannot be deter- 
mined from these transfection studies. However, the find- 
ings  indicate  that  the  FucT-IV  enzyme synthesizes low 
avidity E-selectin ligands when expressed at very high lev- 
els  and  that  the  sLeX-moiety is  probably not  the  active 
structure. 
The  contributions  of  the  two  fucosyltransferases  to 
E-selectin ligand  synthesis appears to be lineage depen- 
dent.  Granulocytes, monocytes, myeloid cells  lines,  and 
E-selectin ligand-positive  lymphoid cells  all  express  the 
sLeX-related  epitopes  at  levels  found  on  the  FucT-VII 
transfectants.  In  contrast,  only neutrophils  and  myeloid 
cell lines express the CDw65 epitope at the level found on 
the FucT-IV transfectants (Table I). In keeping with their 
phenotype, the myeloid cell lines contain very high levels 
of mRNA  and  enzymatic activity for both fucosyltrans- 
ferases.  The  E-ligand  positive  T-lymphoblasts,  on  the 
other hand, express high levels of FucT-VII activity but 
10-fold lower levels of FucT-IV activity than the myeloid 
cells (Fig. 8). Thus, the level of FucT-IV activity in T-lym- 
phoblasts is sufficient to synthesize the Le  x epitope but not 
high enough to synthesize the CDw65 epitope or E-selec- 
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and neutrophils (or their precursors) contain enough en- 
zyme to synthesize E-selectin ligands functional at physio- 
logic levels of linear-shear stress. Consequently, we conclude 
that both fucosyltransferases may regulate E-selectin bind- 
ing activity in myeloid cells but that FucT-VII is the pre- 
dominant enzyme in T-lymphoblasts. 
The synthetic pathway identified in this study may regu- 
late the trafficking of both normal and malignant T cells in 
vivo. Picker and colleagues report that the prevalence of 
the HECA452 epitope (also known as CLA) is highest on 
T-lymphoblasts generated in lymphoid organs draining the 
skin (33). Both the HECA452 and CSLEX1 epitopes are 
strongly expressed on a subset of the T-lymphoblasts un- 
dergoing the naive to memory transition in these organs. 
In contrast, memory T-lymphocytes  with E-selectin ligands 
in the circulation frequently express the HECA452 epitope 
at higher levels than CSLEX1. HECA452-positive mem- 
ory T cells also accumulate in cutaneous inflammatory/im- 
munologic lesions in association with E-selectin positive 
venules (28, 30, 31). In addition, the HECA452 epitope is 
strongly expressed on T  cell lymphomas infiltrating skin 
(4)  and the prevalence of the epitope on the circulating 
malignant  T  cells  correlates with  the  extent of skin  in- 
volvement (12). Thus, E-selectin may promote the recruit- 
ment  of HECA452  positive normal  and  malignant  cells 
from the bloodstream into the skin. 
The current study shows that the FucT-VII enzyme con- 
trols expression of both the HECA452 epitope and E-selec- 
tin  ligands  on  T-lymphoblasts.  Furthermore,  it  demon- 
strates  that  the  medium  in  which  T  cell  activation  and 
proliferation  occurs  influences  HECA452  and  E-ligand 
synthesis  through  pretranscriptional  regulation  of  the 
FucT-VII gene product.  Consequently, we  propose that 
modulation of the FucT-VII gene product during the anti- 
gen-driven proliferation of T-lymphoblasts in vivo deter- 
mines the level of E-selectin ligands on the memory cells 
reentering the circulation thus influences their subsequent 
trafficking pattern.  Similarly, upregulation  of the  FucT- 
VII gene product in malignant cells will induce high avid- 
ity ligands for E-selectin and may account for metastases 
to E-selectin rich tissues such as the skin. Finally, the ob- 
servation that rising FucT-VII levels in PMA-treated Jur- 
kat cells upregulates HECA452 expression at a faster rate 
than CSLEX1  suggests that the relative densities of the 
two epitopes depend on the level or duration of FucT-VII 
activity. Therefore, the  differences in  the  ratio  of these 
two epitopes  on T-lymphoblasts from lymph nodes  and 
memory T cells from peripheral blood may reflect a fall in 
the level of FucT-VII as the cells enter a resting state. The 
competitive RT-PCR techniques needed to test these hy- 
potheses directly on the relatively small number of T cells 
regulating selectin ligands in vivo are currently under de- 
velopment. However, the current study provides a mecha- 
nistic foundation for these studies by identifying the synthetic 
pathway  and control points likely to regulate E-selectin 
ligand synthesis in vivo. 
In summary, this study provides the first evidence that 
modulation  of  fucosyltransferase  activity  regulates  the 
synthesis of E-selectin ligands during T cell activation/pro- 
liferation. Both the FucT-VII and FucT-IV enzymes con- 
tribute to the synthesis of E-selectin ligands on human leu- 
kocytes. However, the FucT-VII enzyme predominates in 
T cells while both participate in ligand production by mye- 
loid cells. In addition to E-ligand synthesis, FucT-VII reg- 
ulates expression of the CSLEX1 and HECA452 epitopes 
while FucT-IV regulates CD15 and CDw65 levels on leu- 
kocytes. Whether these carbohydrate epitopes form part 
of the endogenous E-selectin ligands on T-lymphoblasts or 
other leukocytes remains to be determined. Nonetheless, 
the findings herein suggest that inhibitors of the FucT-VII 
enzyme, in particular, will suppress E-selectin-dependent 
inflammatory  and  immunologic  diseases.  Furthermore, 
specific blockade of this enzyme may prevent ligand syn- 
thesis by T cells while preserving low-level, FucT-IV medi- 
ated  production in  neutrophils.  As  a  consequence, such 
agents may inhibit selectin-dependent chronic inflamma- 
tory diseases in the skin and elsewhere without the global 
suppression  of inflammation  that  limits  treatment  with 
currently available drugs. 
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